Enhanced Corneal Endothelial Disease Treatment System
Legal Citation
Summary of the Inventive Concept
The present inventive concept relates to novel improvements and enhancements to the original composition or method for treating or preventing corneal endothelial diseases using (T)EW-7197, providing better efficacy, safety, and patient outcomes.
Background and Problem Solved
The original patent disclosed a composition or method for treating or preventing corneal endothelial diseases using (T)EW-7197. However, there remained limitations in terms of efficacy, safety, and patient outcomes. The present inventive concept addresses these limitations by providing direct improvements and enhancements to the original invention, resulting in better treatment outcomes for patients.
Detailed Description of the Inventive Concept
The present inventive concept encompasses a system for treating or preventing corneal endothelial diseases, comprising a topical formulation of (T)EW-7197 and a corneal endothelial cell-targeting moiety, which enhances corneal endothelial cell migration and proliferation. Additionally, the inventive concept includes a method for enhancing the efficacy of (T)EW-7197 by co-administering it with a Rho-kinase inhibitor, a pharmaceutical composition forming a sustained-release matrix, a method for reducing the incidence of corneal endothelial disease recurrence, and a kit for treating or preventing corneal endothelial diseases.
Novelty and Inventive Step
The present inventive concept's novelty lies in the combination of (T)EW-7197 with a corneal endothelial cell-targeting moiety, the co-administration with a Rho-kinase inhibitor, the sustained-release matrix composition, and the corneal endothelial cell-based therapy. These combinations and enhancements provide a non-obvious solution to the limitations of the original patent, resulting in improved treatment outcomes.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include varying the type of corneal endothelial cell-targeting moiety, the specific Rho-kinase inhibitor used, the composition of the sustained-release matrix, or the specific corneal endothelial cell-based therapy employed. These variations can be used to tailor the treatment to specific patient needs or disease types.
Potential Commercial Applications and Market
The present inventive concept has significant commercial potential in the ophthalmology market, particularly in the treatment of corneal endothelial diseases such as Fuchs' endothelial corneal dystrophy and corneal guttata. The improved efficacy, safety, and patient outcomes offered by the inventive concept can lead to increased adoption and market share.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical compositions for corneal endothelial disease treatment, involving medicinal chemistry, ophthalmology, and targeted drug delivery systems
Person of Ordinary Skill (PHOSITA) Profile
A researcher with advanced degree in pharmaceutical sciences or ophthalmology, familiar with drug formulation techniques, cell targeting strategies, and corneal disease treatment approaches
Obviousness Rationale
A PHOSITA would recognize that enhancing (T)EW-7197's delivery and efficacy through targeted moieties, sustained release matrices, and combination therapies represents predictable extensions of the source patent's core therapeutic approach. The disclosed variations apply standard pharmaceutical optimization techniques to improve the original compound's clinical utility. These modifications demonstrate routine problem-solving within the corneal disease treatment domain.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,544 |
|---|---|
| Title | Composition or method including (t)ew-7197 for treating or preventing corneal endothelial diseases |
| Assignee(s) | SENJU PHARMACEUTICAL CO., LTD., THE DOSHISHA |